Healthcare
ZyVersa Therapeutics, Inc.(ZVSA)
Live Price
Offline$0.189
+11.83% today
1Y Change
-67.90%
Window
Jun 23, 2025 โ Jun 5, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +50.7%
- Dividend Yield
- 0.0%
Coverage: 241 bars ยท Jun 23, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ZyVersa Therapeutics, Inc. (ZVSA) is a Healthcare stock with listed on OTC. The stock last traded around $0.19 and down 67.9% across the available one-year price window (Jun 23, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.7%, free cash flow -67553.3% with operating margin 0.0% and ROIC 0.1%. Stock Foundry combines ZVSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +50.7%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -5.3% | -2.6% | โ |
2026 Mar 31, 2026 | -43.3% | +0.0% | -5.0% | +5.0% |
2025 Nov 19, 2025 | โ | +3.7% | +8.9% | +4.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZVSA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZVSA Max Drawdown
-85.16%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZVSA and SPY.
Company Overview
ZyVersa Therapeutics, Inc.
Other OTC
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
- Leadership
- Stephen C. Glover
- IPO Date
- Feb 11, 2022
- Employees
- 7
- Street Address
- 2200 N. Commerce Parkway
- Mailing
- Weston, FL, 33326
- Region
- Weston, FL, US
- Reporting Currency
- USD
- Investor Line
- 754 231 1688
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 4.0
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +50.7%
- Free Cash Flow
- -67553.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.8%
- ROIC
- 0.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.